Fig. 4: EGFR inhibition reduces the hypertrophic phenotype and lysosomal defects in NAGLU-silenced H9C2 cardiomyoblasts. | Cell Death & Disease

Fig. 4: EGFR inhibition reduces the hypertrophic phenotype and lysosomal defects in NAGLU-silenced H9C2 cardiomyoblasts.

From: EGFR activation triggers cellular hypertrophy and lysosomal disease in NAGLU-depleted cardiomyoblasts, mimicking the hallmarks of mucopolysaccharidosis IIIB

Fig. 4

a Representative images of actin cytoskeleton stained with phalloidin of H9C2 sh-CTR and H9C2 sh-NAGLU, both untreated and treated for 24 h with 10 μM of AG1478. Scale bars: 10 μm. A significant reduction of cell size was observed in AG1478-treated NAGLU-depleted H9C2 (lower panels), while no effect was detected in H9C2 sh-CTR clones (upper panels). Quantification of cell size is the mean ± SD of three independent experiments. *P < 0.05. b Representative images of the lysosomes labeled by LysoTracker probe in H9C2 sh-CTR and H9C2 sh-NAGLU, both untreated and treated for 24 h with 10 μM of AG1478. Scale bars: 10 μm. In the AG1478-treated H9C2 sh-NAGLU, lysosome staining was significantly reduced compared to the untreated clones (lower panels), while no effect was detected in H9C2 sh-CTR clones (upper panels). Quantification of LysoTracker staining is the mean ± SD of three independent experiments. *P < 0.05

Back to article page